Patents by Inventor Robert J. Chorvat

Robert J. Chorvat has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ULTRA SHORT ACTING ANTI-ARRHYTHMIC AGENTS
    Publication number: 20240025846
    Abstract: Some aspects provide novel dofetilide derivatives and pharmaceutical compositions containing the same that are useful as pharmaceutical agents in the treatment of supraventricular and ventricular arrhythmias.
    Type: Application
    Filed: July 6, 2023
    Publication date: January 25, 2024
    Inventors: John Somberg, Robert J. Chorvat
  • Ultra short acting anti-arrhythmic agents
    Patent number: 11731938
    Abstract: Some aspects provide novel dofetilide derivatives and pharmaceutical compositions containing the same that are useful as pharmaceutical agents in the treatment of supraventricular and ventricular arrhythmias.
    Type: Grant
    Filed: December 22, 2021
    Date of Patent: August 22, 2023
    Assignee: Academic Pharmaceuticals Inc
    Inventors: John Somberg, Robert J Chorvat
  • ULTRA SHORT ACTING ANTI-ARRHYTHMIC AGENTS
    Publication number: 20220213032
    Abstract: Some aspects provide novel dofetilide derivatives and pharmaceutical compositions containing the same that are useful as pharmaceutical agents in the treatment of supraventricular and ventricular arrhythmias.
    Type: Application
    Filed: December 22, 2021
    Publication date: July 7, 2022
    Inventors: John Somberg, Robert J Chorvat
  • Ultra short acting anti-arrhythmic agents
    Patent number: 11286235
    Abstract: The present invention provides novel sotalol derivatives and pharmaceutical compositions containing the same that are are useful as pharmaceutical agents in the treatment of supraventricular and ventricular arrhythmias.
    Type: Grant
    Filed: October 5, 2020
    Date of Patent: March 29, 2022
    Assignee: Academic Pharmaceuticals, Incorporated
    Inventors: John Somberg, Robert J Chorvat
  • Cannabinoid receptor antagonists/inverse agonists useful for treating disease conditions, including metabolic disorders and cancers
    Patent number: 11179370
    Abstract: The present invention provides novel, diastereomeric pyrazolines that are useful as cannabinoid receptor blockers and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, inflammatory disorders, cardiometabolic disorders, hepatic disorders, and/or cancers.
    Type: Grant
    Filed: March 4, 2020
    Date of Patent: November 23, 2021
    Assignee: Jenrin Discovery, LLC
    Inventors: John F McElroy, Robert J. Chorvat
  • ULTRA SHORT ACTING ANTI-ARRHYTHMIC AGENTS
    Publication number: 20210107867
    Abstract: The present invention provides novel sotalol derivatives and pharmaceutical compositions containing the same that are are useful as pharmaceutical agents in the treatment of supraventricular and ventricular arrhythmias.
    Type: Application
    Filed: October 5, 2020
    Publication date: April 15, 2021
    Inventors: John Somberg, Robert J Chorvat
  • CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING DISEASE CONDITIONS, INCLUDING METABOLIC DISORDERS AND CANCERS
    Publication number: 20210023054
    Abstract: The present invention provides novel, diastereomeric pyrazolines that are useful as cannabinoid receptor blockers and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, inflammatory disorders, cardiometabolic disorders, hepatic disorders, and/or cancers.
    Type: Application
    Filed: March 4, 2020
    Publication date: January 28, 2021
    Inventors: John F. McElroy, Robert J. Chorvat
  • Ultra short acting anti-arrhythmic agents
    Patent number: 10793519
    Abstract: The present invention provides novel sotalol derivatives and pharmaceutical compositions containing the same that are are useful as pharmaceutical agents in the treatment of supraventricular and ventricular arrhythmias.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: October 6, 2020
    Assignee: Academic Pharmaceuticals Incorporated
    Inventors: John Somberg, Robert J Chorvat
  • Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
    Patent number: 10617673
    Abstract: The present invention provides novel, diastereomeric pyrazolines that are useful as cannabinoid receptor blockers and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, inflammatory disorders, cardiometabolic disorders, hepatic disorders, and/or cancers.
    Type: Grant
    Filed: May 29, 2018
    Date of Patent: April 14, 2020
    Assignee: Jenrin Discovery, LLC
    Inventors: John F McElroy, Robert J Chorvat
  • ULTRA SHORT ACTING ANTI-ARRHYTHMIC AGENTS
    Publication number: 20190352257
    Abstract: The present invention provides novel sotalol derivatives and pharmaceutical compositions containing the same that are are useful as pharmaceutical agents in the treatment of supraventricular and ventricular arrhythmias.
    Type: Application
    Filed: April 30, 2019
    Publication date: November 21, 2019
    Inventors: John Somberg, Robert J Chorvat
  • CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES
    Publication number: 20180353478
    Abstract: The present invention provides novel, diastereomeric pyrazolines that are useful as cannabinoid receptor blockers and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, inflammatory disorders, cardiometabolic disorders, hepatic disorders, and/or cancers.
    Type: Application
    Filed: May 29, 2018
    Publication date: December 13, 2018
    Inventors: John F. McElroy, Robert J. Chorvat
  • Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
    Patent number: 9987253
    Abstract: The present invention provides novel, diastereomeric pyrazolines that are useful as cannabinoid receptor blockers and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, inflammatory disorders, cardiometabolic disorders, hepatic disorders, and/or cancers.
    Type: Grant
    Filed: December 13, 2016
    Date of Patent: June 5, 2018
    Assignee: JENRIN DISCOVERY, INC.
    Inventors: John F McElroy, Robert J Chorvat
  • CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES
    Publication number: 20170182004
    Abstract: The present invention provides novel, diastereomeric pyrazolines that are useful as cannabinoid receptor blockers and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, inflammatory disorders, cardiometabolic disorders, hepatic disorders, and/or cancers.
    Type: Application
    Filed: December 13, 2016
    Publication date: June 29, 2017
    Inventors: John F. McElroy, Robert J. Chorvat
  • Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
    Patent number: 9517228
    Abstract: The present invention provides novel, diastereomeric pyrazolines that are useful as cannabinoid receptor blockers and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, inflammatory disorders, cardiometabolic disorders, hepatic disorders, and/or cancers.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: December 13, 2016
    Assignee: Jenrin Discovery, Inc.
    Inventors: John F McElroy, Robert J Chorvat
  • CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES
    Publication number: 20160058736
    Abstract: The present invention provides novel, diastereomeric pyrazolines that are useful as cannabinoid receptor blockers and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, inflammatory disorders, cardiometabolic disorders, hepatic disorders, and/or cancers.
    Type: Application
    Filed: September 3, 2015
    Publication date: March 3, 2016
    Inventors: John F McElroy, Robert J Chorvat
  • Cannabinoid receptor antagonists/inverse agonists useful for treating disease conditions, including metabolic disorders and cancers
    Patent number: 9133127
    Abstract: The present invention provides novel, diastereomeric pyrazolines that are useful as cannabinoid receptor blockers and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, inflammatory disorders, cardiometabolic disorders, hepatic disorders, and/or cancers.
    Type: Grant
    Filed: February 27, 2014
    Date of Patent: September 15, 2015
    Assignee: Jenrin Discovery, Inc.
    Inventors: John F. McElroy, Robert J. Chorvat
  • CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES
    Publication number: 20150157605
    Abstract: The present invention provides novel pyrazoles that are useful as cannabinoid receptor antagonists and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, hepatic disorders, and/or cardiometabolic disorders.
    Type: Application
    Filed: October 6, 2014
    Publication date: June 11, 2015
    Inventors: John F. McElroy, Robert J. Chorvat
  • CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING DISEASE CONDITIONS, INCLUDING METABOLIC DISORDERS AND CANCERS
    Publication number: 20140329875
    Abstract: The present invention provides novel, diastereomeric pyrazolines that are useful as cannabinoid receptor blockers and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, inflammatory disorders, cardiometabolic disorders, hepatic disorders, and/or cancers.
    Type: Application
    Filed: February 27, 2014
    Publication date: November 6, 2014
    Applicant: JENRIN DISCOVERY
    Inventors: John F. McElroy, Robert J. Chorvat
  • Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
    Patent number: 8853252
    Abstract: The present invention provides novel pyrazoles that are useful as cannabinoid receptor antagonists and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, hepatic disorders, and/or cardiometabolic disorders.
    Type: Grant
    Filed: March 7, 2012
    Date of Patent: October 7, 2014
    Assignee: Jenrin Discovery, Inc.
    Inventors: John F. McElroy, Robert J. Chorvat
  • 4-quinolinemethanols as anti-malarial agents
    Patent number: 8716265
    Abstract: The present invention relates to substituted 4-qinolinemethanols and pharmaceutical compositions thereof and methods of using the same for treating of malaria, tuberculosis, and other infectious diseases.
    Type: Grant
    Filed: November 18, 2011
    Date of Patent: May 6, 2014
    Assignee: Jenrin Discovery, Inc.
    Inventors: John F. McElroy, Robert J. Chorvat, David Nugiel